课题基金 / 基金详情

PHASE I/II TRIAL OF PSC 833 AND OTHERS IN NONHODGKINS LYMPHOMA

PHASE I/II TRIAL OF PSC 833 AND OTHERS IN NONHODGKINS LYMPHOMA
PSC 833 和其他药物治疗非霍奇金淋巴瘤的 I/II 期试验
批准号:
6246162
负责人:
SANDRA J. HORNING
金额:
$3.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-05-15 至 1997-11-30

项目摘要

项目成果

SANDRA J. HORNING的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Expression of the mdr1 gene may be an important cause of chemotherapy failure in patients with Non-Hodgkin's Lymphoma. ONCEP (Vincristine(0), Novantrome (N), Cyclophophamide (C), Etoposide (E), and Prednisone (P)) chemotherapy contains three MDR (Multi-drug resistance) realated agents (O N, E) and was designed for studies of MDR modulation. PSC 833 is a non-immunosuppressive cyclosporine with greater in vitro MDR modulating activity that Cyclosporin A. ONCEP-PSC chemotherapy is well tolerated and has significant activity in patients with recurrent or refractory NHL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autografting for Lymphoma
  • 批准号:
    8260362
  • 项目类别:
  • 资助金额:
    $35.17万
  • 财政年份:
    2011
  • 负责人:
    SANDRA J. HORNING
  • 依托单位:
Autografting for Lymphoma
  • 批准号:
    7212897
  • 项目类别:
  • 资助金额:
    $33.28万
  • 财政年份:
    2007
  • 负责人:
    SANDRA J. HORNING
  • 依托单位:
EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOMINANT HODGKIN'S DISEASE
  • 批准号:
    7605162
  • 项目类别:
  • 资助金额:
    $2.11万
  • 财政年份:
    2007
  • 负责人:
    SANDRA J. HORNING
  • 依托单位:
CLINICAL TRIAL: EVALUATE THE EFFICACY OF ANTI-CD20 ANTIBODY IN LYMPHOCYTE PREDOM
  • 批准号:
    7717845
  • 项目类别:
  • 资助金额:
    $0.36万
  • 财政年份:
    2007
  • 负责人:
    SANDRA J. HORNING
  • 依托单位:
海外基金